Reports Q3 revenue $180,000. “The third quarter was exciting for Trevena as we reported promising proof-of-concept data for our two TRV045 studies, including favorable safety and tolerability topline data, and strengthened our balance sheet with the receipt of the $15 million dollar R-Bridge tranche,” said Carrie Bourdow, President and CEO of Trevena. “There is a significant need for safe and effective non-opioid therapies in pain, and for novel mechanisms for the treatment of epilepsy. By the end of the year we anticipate receipt of topline data for TRV045 from the NIH nonclinical seizure prevention study, and we look forward to updating you on the next steps of our plan to advance TRV045, on our own or with a strategic partner, for potential treatment of neuropathic pain, epilepsy and other CNS disorders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TRVN:
- Trevena Reports Third Quarter 2023 Results and Provides Business Update
- Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023
- Is TRVN a Buy, Before Earnings?
- Trevena reports favorable TRV045 safety, tolerability data
- Trevena completes initial analysis of OLINVYK respiratory monitoring data